ESMO Congress 2019: ESMO Colloquia

The ESMO Colloquia are innovative new sessions within the Congress programme that bring together top experts to discuss evolving areas of interest to the oncology community.

The Colloquia are organised by ESMO and supported by the industry in a unique collaboration making them the perfect complement to the scientific and education programme of the Congress.

View the complete ESMO Congress 2019 programme online

Saturday, 28 September 2019

ESMO Colloquium: Emerging biotherapy strategies in the treatment of solid tumours: Hope, Hype and Hurdles

Room Toledo, 13:00-14:30
This educational activity is provided by ESMO and supported by Eisai Europe.

Learning Objectives

  • Understand how the development of TKI have changed practice and treatment prioritization
  • Review the overall outcome with the development of Immuno-Oncology and practice changes
  • Look forward to the development of Combined approaches with TKI and Immuno-Oncology

Sunday, 29 September 2019

ESMO Colloquium: Metastatic clear cell renal cell carcinoma: How to navigate within multiple options and risk groups? What is the best sequence in a multi-line setting?

Room Cordoba, 18:30-20:00
This educational activity is provided by ESMO and supported by Ipsen.

Learning Objectives

  • Review the 2019 algorithms from the ESMO Guidelines management of Renal Cell Carcinoma
  • Compare the outcome and clinical benefit (ESMO-MCBS) of the various therapeutic options according to risk factors upfront and in later lines.
  • Discuss the best sequencing of drug use considering the large choice of approved agents

Sunday, 29 September 2019

ESMO Colloquium: Relapsed/Refractory FLT3-ITD positive Acute Myeloid Leukemias (AML)

Room Toledo, 18:30-20:00
This educational activity is provided by ESMO and supported by Daiichi Sankyo Europe GmbH.

Learning Objectives

  • Review the present characteristics and Guidelines for the management of Relapsed/Refractory AML
  • Understand the mechanism of action of FLT3 and its role in AML when mutated
  • Review the recent outcomes of FLT3-ITD as a target in Relapsed/Refractory AML

Sunday, 29 September 2019

ESMO Colloquium: Metastatic gastro-intestinal cancer: Multiple treatment lines, extended pipeline of available drugs and use of predictive markers. How to best sequence the treatment proposal?

Room Alicante, 18:30-20:00
This educational activity is provided by ESMO and supported by Lilly Oncology.

Learning Objectives

  • Based on a case presentation
  • Discuss the best sequence and level of evidence
  • Learn how the use of biomarker to help the decision
  • Review the guidelines algorithms and ESMO-MCBS scores as tools for selection

Monday, 30 September 2019

ESMO Colloquium: Pancreatic cancer: Can better understanding of biology improve resectability and survival?

Room Alicante, 13:00-14:30
This educational activity is provided by ESMO and supported by Celgene.

Learning Objectives

  • Learn on the biological peculiar aspects of pancreatic cancer and treatment resistance
  • Review the present state of art of medical treatment improving resectability and survival
  • Get the point of view of the specialized surgeon on resectabilitiy criteria and issues
  • Review the present development of new drugs including targeted and Immuno-oncology agents

Monday, 30 September 2019

ESMO Colloquium: Recurrent glioblastoma management: Challenges and opportunities

Room Salamanca, 18:30-20:00
This educational activity is provided by ESMO and supported by Apogenix.

Learning Objectives

  • Review the present standard of care management of recurrent glioblastoma
  • Access the landscape of present new development for the treatment of recurrent glioblastoma
  • Understand the role and biological mechanisms of CD95/Fas/CD95L signaling pathway
  • Deliver an update of the present clinical results of CD95L/FAS/FAS-Ligand blockade